* Neose Pharmaceuticals Inc., of Philadelphia, expanded its 1992agreement on development of complex carbohydrates with AbbottLaboratories, of Abbott Park, Ill. Financial terms were not disclosed.
* Organogensis Inc., of Canton, Mass., said interim results of apivotal trial of its manufactured human skin product, Graftskin,showed statistical significance when compared with therapeuticcompression therapy in treating venous ulcers. Complete data on the300-patient trial is expected this spring.
* Inflazyme Pharmaceuticals Ltd., of Vancouver, Canada, said IZP-94005 successfully prevented allergic asthmatic reactions andreduced bronchial hyperresponsiveness in a sheep model of asthma.IZP-94005 is an anti-inflammatory drug found to be effective byinhalation or oral administration.
* Medimmune Inc., of Gaithersburg, Md., began Phase I trials of itsMedi-491 vaccine for B19 parvovirus, which is an infection that killscells that produce red blood cells. Medi-491 is derived from thecompany's virus-like-particle technology, which creates a vaccinethat resembles natural B19 parvovirus particles, but is not infectious.Results of the study are expected by the end of 1995.
* Vical Inc., of San Diego, began Phase I/II trials of its Leuvectincancer gene therapy at the Arizona Cancer Center in Tucson.Twenty-five patients with advanced solid tumors or lymphoma willparticipate in the studies. Leuvectin is injected into tumors andcontains a gene that encodes interleukin-2, which is believed tostimulate the immune system to attack the tumor. Leuvectin is thecompany's second gene therapy product in clinical trials.
* Intercardia Inc., of Lexington, Mass., began Phase III studies ofbucindolol for treatment of congestive heart failure. The company, asubsidiary of Interneuron Pharmaceuticals, also of Lexington, saidthe trials are the first beta blocker studies aimed at measuring theimpact of the drug on mortality in congestive heart failure.
* Cypros Pharmaceutical Corp., of Carlsbad, Calif., said its commonstock (CYPR) and redeemable Class B warrants are listed on theNASDAQ National Market System.
* Paracelsian Inc., of Ithaca, N.Y., said initial screenings of sixChinese medicinal compounds indicate that four have anti-cancerproperties. Those compounds will undergo additional tests in prostatecancer cell lines at Roswell Park Memorial Cancer Institute inBuffalo, N.Y.
* CytoProbe Corp., of San Diego, raised $1 million in a privateplacement to help fund continued development of its three majormedical device products.
* Matritech Inc., of Cambridge, Mass., signed a licensing agreementwith Yale University, of New Haven, Conn., giving the companyexclusive rights to the university's discovery of a new group ofproteins used to screen cancer drugs.
* NeXstar Pharmaceuticals Inc., of Boulder, Colo., said it willpresent data from its Phase III trial of DaunoXome for advancedKaposi's sarcoma at the June 8-9 meeting of the FDA's OncologyDrugs Advisory Committee.
* ID Biomedical Corp., of Vancouver, British Columbia, signed aresearch agreement with Corange International Ltd., of Hamilton,Bermuda, to evaluate ID's technology for in vitro diagnostics.
(c) 1997 American Health Consultants. All rights reserved.